SHELTON, Conn. , Feb. 5, 2014 -- Cara Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price ... (more)
via Shelton Newswire http://ift.tt/1bsgAMB
via Shelton Newswire http://ift.tt/1bsgAMB
No comments:
Post a Comment